Dr. Cesar A. Santa-Maria
Claim this profileJohns Hopkins University
Area of expertise
Breast Cancer
Cesar A. Santa-Maria has run 11 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Cesar A. Santa-Maria has run 7 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Johns Hopkins University
Johns Hopkins University/Sidney Kimmel Cancer Center
Clinical Trials Cesar A. Santa-Maria is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Immunotherapy + Chemotherapy
for Triple Negative Breast Cancer
This trial tests a new combination of two immune-boosting drugs and a chemotherapy drug in patients with hard-to-treat breast cancer. The goal is to see if this combination is safe and effective at controlling the cancer.
Recruiting
1 award
Phase 1
13 criteria
More about Cesar A. Santa-Maria
Clinical Trial Related
8 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Cesar A. Santa-Maria has experience with
- Olaparib
- Paclitaxel
- Cyclophosphamide
- Doxorubicin
- Avelumab
- Durvalumab
Breakdown of trials Cesar A. Santa-Maria has run
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Cesar A. Santa-Maria specialize in?
Cesar A. Santa-Maria focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Cesar A. Santa-Maria currently recruiting for clinical trials?
Yes, Cesar A. Santa-Maria is currently recruiting for 6 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Cesar A. Santa-Maria has studied deeply?
Yes, Cesar A. Santa-Maria has studied treatments such as Olaparib, Paclitaxel, Cyclophosphamide.
What is the best way to schedule an appointment with Cesar A. Santa-Maria?
Apply for one of the trials that Cesar A. Santa-Maria is conducting.
What is the office address of Cesar A. Santa-Maria?
The office of Cesar A. Santa-Maria is located at: Johns Hopkins University, Baltimore, Maryland 21218 United States. This is the address for their practice at the Johns Hopkins University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.